| Ytd | 31.06% | |
| 1y | 1797.85% |
| Open | 52.97 | Prev Close | 52.93 | Low | 52.94 | High | 52.98 | Mkt Cap | 4.77B |
| Vol | 0.00 | Avg Vol | 5.92M | EPS | -1.03 | P/E | -51.41 | Forward P/E | -34.01 |
| Beta | -0.37 | Short Ratio | 0.70 | Inst. Own | 109.69% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-07 | 50-d Avg | 50.15 | 200-d Avg | 29.48 | 1yr Est | 53.00 |
TERN News
Tern PLC (AIM:TERN) shares surged some 30% higher, to 1.18p, after it increased exposure to Talking
https://www.bloomberg.com/news/articles/2026-05-18/merck-starts-seven-part-high-grade-bond-sale-to-f
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Cana
Merck retains a 'strong buy' rating, driven by proactive oncology pipeline expansion to offset KEYTR
Merck MRK is set to report its first-quarter 2026 earnings on April 30, before market open. The Zac
Designation for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloi
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Cana
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following compan
All told, the transaction is valued at around $6.7 billion. If all goes well, it'll close this quart
The deal consideration is $53.00 per share in cash for an approximate equity value of $6.7 billion.
Merck begins tender offer for Terns at $53 per share as part of its planned acquisition announced in
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Cana
MILWAUKEE, April 07, 2026 (GLOBE NEWSWIRE) -- Ademi LLP is investigating Terns (NASDAQ: TERN) for po
Capricorn Fund Managers Ltd bought a new stake in shares of Terns Pharmaceuticals, Inc. (NASDAQ: TER
FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the
Pre-Market Stock Futures: Futures are trading higher this morning after reports are circulating that
Top Wall Street analysts changed outlook on top names. For all changes, including upgrades/downgrade
Pre-Market Stock Futures: Futures are trading lower as we prepare to end another up-and-down week, a
MRK's $6.7B Terns buyout is set to add a promising leukemia drug candidate, boosting its oncology pi
E. Ohman J or Asset Management AB lessened its position in shares of Terns Pharmaceuticals, Inc. (NA
Shares of Terns Pharmaceuticals, Inc. (NASDAQ: TERN - Get Free Report) reached a new 52-week high du
Wall Street analysts changed their outlook on top names. Check analyst ratings page for upgrades, do
On Monday, 198 companies reached new 52-week lows.
On Friday, 431 companies hit new 52-week lows.
On Monday, 71 stocks hit new 52-week lows.
On Friday, 209 companies set new 52-week lows.